New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.98
2.24
+1.69%
Follow MRK
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $3.63 was left as profit. Gross margin has fallen three quarters running, from 74.8% to 71.8%. What is an income statement?
| Revenue | 67.4 | 100.0% |
|---|---|---|
| Cost of revenue | −19.0 | −28.2% |
| Gross profit | 48.3 | 71.8% |
| Research & development | −30.8 | −45.6% |
| Selling, general & admin | −11.4 | −16.9% |
| Operating income | 6.2 | 9.2% |
| Other income, net | −1.4 | −2.1% |
| Income tax | −2.3 | −3.4% |
| Net income | 2.4 | 3.6% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $65.0B | $65.8B | $66.6B | $67.4B |
| Operating income | $22.1B | $13.0B | $7.0B | $6.2B |
| Net income | $18.3B | $8.9B | $3.2B | $2.4B |
| Net margin (right axis) | 28.1% | 13.6% | 4.8% | 3.6% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Revenue |
+8 more TTM periods Free account |
65,011.00 | 65,768.00 | 66,569.00 | 67,378.00 |
Cost of Revenue |
16,382.00 | 17,158.00 | 17,996.00 | 19,033.00 | |
Gross Profit |
48,629.00 | 48,610.00 | 48,573.00 | 48,345.00 | |
R&D Expenses |
15,789.00 | 24,760.00 | 30,453.00 | 30,756.00 | |
SG&A Expenses |
10,733.00 | 10,881.00 | 11,136.00 | 11,389.00 | |
Operating Income |
22,107.00 | 12,969.00 | 6,984.00 | 6,200.00 | |
Non-operating Income/Expense |
(1,040.00) | (1,339.00) | (1,036.00) | (1,438.00) | |
| 21,067.00 | 11,630.00 | 5,948.00 | 4,762.00 | ||
Income Tax Provision |
2,804.00 | 2,695.00 | 2,778.00 | 2,312.00 | |
Income after Tax |
18,263.00 | 8,935.00 | 3,170.00 | 2,450.00 | |
Non-Controlling Interest |
8.00 | (1.00) | (4.00) | (4.00) | |
Net Income Common |
18,254.00 | 8,935.00 | 3,173.00 | 2,453.00 | |
EPS (Basic) |
7.28 | 3.55 | 1.25 | 0.97 | |
EPS (Diluted) |
7.28 | 3.55 | 1.25 | 0.97 | |
Shares (Basic, Weighted) |
2,507.50 | 2,494.75 | 2,484.75 | 2,478.00 | |
Shares (Diluted, Weighted) |
2,512.25 | 2,497.50 | 2,486.75 | 2,481.75 | |
Gross Margin |
74.80% | 73.91% | 72.97% | 71.75% | |
EBIT Margin |
34.01% | 19.72% | 10.49% | 9.20% | |
EBT margin |
32.41% | 17.68% | 8.94% | 7.07% | |
Net Profit Margin |
28.08% | 13.59% | 4.77% | 3.64% | |
Free Cash Flow Margin |
19.01% | 21.46% | 24.13% | 21.89% | |
EBITDA |
27,945.00 | 19,220.00 | 13,699.00 | 13,544.00 | |
EBIT |
22,107.00 | 12,969.00 | 6,984.00 | 6,200.00 | |
EPS (Diluted, from Cont. Ops) |
7.28 | 3.56 | 1.26 | 0.98 | |
EPS (Diluted, Consolidated) |
7.28 | 3.56 | 1.26 | 0.98 | |
EPS (Basic, Consolidated) |
7.30 | 3.57 | 1.26 | 1.00 | |
Shares (Diluted, Average) |
2,507.50 | 2,492.75 | 2,482.00 | 2,477.00 | |
EPS (Basic, from Continuous Ops) |
7.30 | 3.57 | 1.26 | 1.00 | |
Income from Continuous Operations |
18,263.00 | 8,935.00 | 3,170.00 | 2,450.00 | |
Consolidated Net Income/Loss |
18,263.00 | 8,935.00 | 3,170.00 | 2,450.00 | |
EBITDA Margin |
42.99% | 29.22% | 20.58% | 20.10% | |
Operating Cash Flow Margin |
25.34% | 27.20% | 29.99% | 27.76% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026